A Descriptive Comparison of Phase 3 Results and Head-to-Head Trials in Inflammatory Bowel Diseases.

Date publication

janvier 2026

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Chkolnaia Z, Peyrin-Biroulet L, Uzzan M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41609414

Résumé

With the increasing number of effective therapies for inflammatory bowel diseases (IBD), determining optimal treatment sequences is challenging. Given the impracticality of conducting randomized head-to-head trials for every comparison, this study assessed whether phase 3 placebo-controlled trials can reliably predict outcomes of published head-to-head studies.

Mots clés

Inflammatory bowel disease, head-to-head trial, therapeutic strategy

Référence

J Crohns Colitis. 2026 01 29;: